AstraZeneca Agrees to $110 Million Settlement in Texas Medical Fraud Cases

AstraZeneca has agreed to pay $110 million to settle two lawsuits filed against it by the state of Texas alleging the pharmaceutical giant deceitfully marketed two of its drug products to Texas Medicaid providers.

The state accused AstraZeneca of running false and misleading marketing schemes despite being subject to a 2010 federal corporate integrity agreement that stemmed from prior allegations of health care fraud.

The agreement barred the company from promoting its antipsychotic medication Seroquel (quetiapine fumarate) and its cholesterol medicine Crestor (rosuvastatin calcium) for unapproved FDA uses, but the state alleged the company engaged in off-label marketing anyway.